ClinicalTrials.gg

Program

Erythromycin

Also written as “erythromycin”, “Erythromycin (normal renal function)” and “Erythromycin (mild and moderate renal function)”.

Its studies are mostly in Obesity · Pulmonary Disease, Chronic Obstructive · Renal Insufficiency · Blepharitis · Hepatitis C, led by 2 companies.

Furthest: phase 1, since Feb 17, 20113 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson20 open or runningphase 1since Feb 17, 2011Feb 17, 2011none ahead
Ectycell SASU10 open or runningphase 1since Apr 15, 2011Apr 15, 2011none ahead

Also a collaborator on its studies: Bayer and Bausch Health Companies.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2011First study: phase 1 study in Renal InsufficiencyNew to Johnson & JohnsonJohnson & Johnson · NCT01309438 · 29 enrolled · United States
  2. Mar 10, 2011Phase 1 study in Hepatitis CJohnson & Johnson · NCT01323257 · 49 enrolled · Belgium
  3. Apr 15, 2011Ectycell SASU's first study: phase 1 study in Cardiology: RR / QTNew to Ectycell SASUEctycell SASU · NCT01338441 · 130 enrolled · France

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT01338441Cardiology: RR / QT · France1CompletedEctycell SASUMay 2011130
NCT01323257Hepatitis C · Belgium1CompletedJohnson & Johnson49
NCT01309438Renal Insufficiency · United States1CompletedJohnson & JohnsonMar 201229

How it is read

Names in the registry

  • “Erythromycin”, 5 entries
  • “erythromycin”, 2 entries
  • “Erythromycin (normal renal function)”, 1 entry
  • “Erythromycin (mild and moderate renal function)”, 1 entry
  • “cefuroxime plus erythromycin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.